Investor Presentation First Nine Months of 2022
125
Investor presentation First nine months of 2022
Rest of World at a glance
Rest of World
Diabetes trend in population
Million
DKK
21%
billion
300
250
18%
88
80
200
60
150
286
40
227
40
100
187
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
First nine months
of 2022
Sales
(mDKK)
Growth²
Total GLP-13
5,488
86%
80%
Long-acting insulin4
1,981
13%
Premix insulin5
1,956
4%
60
33%1
GLP-1
Fast-acting insulin
1,834
9%
60%
Human insulin
Insulin
1,975
-11%
1%1
Total insulin
7,746
3%
40%
Other Diabetes care?
417
11%
Diabetes care
13,651
25%
4%1
OAD
50
20
20
20%
Obesity care8
1,456
38%
Diabetes & Obesity
15,107
27%
0
2021
0
0%
care
2030
2045
Aug
2017
Aug
2022
Population with diabetes
Diabetes growth rate
Rare disease⁹
Total
3,741
5%
18,848
22%
GLP-1 MS
-Insulin MS
-OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Aug 2022: Novo Nordisk 57%, Sanofi
24% and Eli Lilly 14%; Competitor GLP-1 value market shares, as of Aug 2022: Novo
Nordisk 62%, Eli Lilly 37% and AstraZeneca 1%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Aug 2022 value
figures
2 At constant exchange rates; 3 Comprises Victoza®, OzempicⓇ and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises NovoMixⓇ and
RyzodegⓇ 6 Comprises NovoRapidⓇ and FiaspⓇ:7 Comprises NovoNormⓇ and
needles;; 8 Comprises SaxendaⓇ: 9 Comprises primarily Esperoct®, Refixia®
,NovoSeven®, Novo Eight® and Norditropin®View entire presentation